Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: Kingfisher who wrote (4163)	7/31/1999 12:34:00 PM
From: DAN LITTLE	Read Replies (1) \| Respond to of 4891

I thought this article was interesting and might help to understand what Dr. H will be addressing. Dan apla.org

To: Kingfisher who wrote (4163)	8/2/1999 11:16:00 AM
From: BARRY ALLEN	Read Replies (3) \| Respond to of 4891

The Chemokines and Chemokine Receptors Conference ain't no two bit poster session like the one in D.C. ,1996, which caused ADVR's price to run from .17 - $1.85. Check out the names of all the Advisors, Chairpersons, and Speakers. We should all be very proud of Dr. Hirschman and company! Scientific Advisors Dr. Marco Baggiolini, University of Bern (Switzerland) Dr. Joan W. Berman, Albert Einstein College of Medicine Dr. Robert W. Doms, University of Pennsylvania Dr. Joseph Hesselgesser, Berlex BioSciences Dr. Thomas J. Schall, Chemocentryx, Inc. Chairpersons Dr. Joan W. Berman, Albert Einstein College of Medicine Dr. Kenneth G. Carson, LeukoSite, Inc. Dr. Joseph Hesselgesser, Berlex BioSciences Dr. Thomas J. Schall, Chemocentryx, Inc. Speakers Dr. Joan W. Berman, Albert Einstein College of Medicine Dr. Arya Biragyn, National Cancer Institute/NIH Dr. Peter Bluford, Sangamo BioSciences, Inc. Dr. Kenneth G. Carson, LeukoSite, Inc. Dr. Bassam Damaj, Tanabe Research Labs-USA Inc. Dr. Dimiter S. Dimitrov, National Cancer Institute/NIH Dr. Jan E. Ehlert, University of Michigan Medical School Dr. Wayne W. Hancock, LeukoSite, Inc. Dr. Joseph Hesselgesser, Berlex BioSciences Dr. Shalom Z. Hirschman, Advanced Viral Research Corporation Dr. Suzanne T. Kanaly, NeoRx Corporation Dr. William Karpus, Northwestern University Medical School Ms. Michelle Lohner, Abgenix, Inc. Dr. Robin Offord, University of Geneva and Gryphon Sciences Dr. Christine A. Power, Serono Pharmaceutical Research (Switzerland) Dr. Richard M. Ransohoff, The Cleveland Clinic Foundation Dr. Thomas J. Schall, Chemocentryx , Inc. Dr. Giovanna Tosato, Center for Biologics Evaluation and Research/FDA Dr. Alexandra Trkola, Rockefeller University Dr. Richard Wyatt, Dana-Farber Cancer Institute Very suprising that no one is jumping on board yet. Maybe ADVR should announce this significant event to the investment community! healthtech.com